Skip to main content

Orchestra BioMed Holdings, Inc.

corporate_fare Company Profile

Orchestra BioMed Holdings, Inc.

OBIO·NASDAQ·Industrial Applications And Services·CIK 0001814114

Orchestra BioMed Holdings, Inc. is a biomedical innovation company that accelerates high-impact medical technologies to patients through strategic collaborations with market-leading global medical device companies. The company was formed in 2018 and is led by a multidisciplinary management team and board of directors with extensive experience in therapeutic device development. Orchestra BioMed's flagship product candidates are Atrioventricular Interval Modulation Therapy ("AVIM Therapy") for hypertension ("HTN") and Virtue® Sirolimus AngioInfusion™ Balloon ("Virtue SAB") for atherosclerotic artery disease. HTN is the leading risk factor for death worldwide, and atherosclerotic artery disease is the leading cause of mortality worldwide. The company has an exclusive license and collaboration agreement with Medtronic, Inc. for the development and commercialization of AVIM Therapy. Orchestra BioMed is currently conducting the "BACKBEAT study," a double-blind, randomized, global pivotal study enrolling up to 500 patients with uncontrolled hypertension who are indicated for a Medtronic dual-chamber pacemaker. Enrollment completion for the BACKBEAT study is currently planned for mid-2026. Orchestra BioMed recently initiated patient enrollments in the "Virtue Trial" for its U.S. investigational device exemption ("IDE") pivotal study. This trial randomizes Virtue SAB against Boston Scientific Corporation's AGENT™ drug-coated balloon for the treatment of coronary in-stent restenosis ("ISR"). The Virtue Trial is designed to support regulatory approval of Virtue SAB and is expected to enroll 740 patients in the United States, with enrollment completion currently planned for mid-2027. AVIM Therapy is a bioelectronic therapy candidate designed to lower blood pressure and can be integrated as a firmware upgrade to standard cardiac pacemakers. HTN affects over 70% of pacemaker-indicated patients, making AVIM Therapy a potentially attractive therapeutic solution for this population.

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 19 items for OBIO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 19 most recent items scored 7 or higher, the top rating is 9/10, with 8 rated 8 or above. Recent SEC coverage for OBIO spans 4, 10-Q, 424B5, SCHEDULE 13D/A.

Recent high-impact activity:

  • 10% Owner RTW Buys $6M of Orchestra BioMed Stock at the $5.00 Offering Price
  • Orchestra BioMed Q3 Loss Narrows to $18.8M; Cash Runway Extended to 2028
  • Orchestra BioMed Prices $75M Offering at $5.00, a Discount to the $5.62 Last Sale
  • Orchestra BioMed Prices 15M-Share Offering at $5.00
  • Orchestra BioMed Launches Underwritten Stock Offering to Fund BACKBEAT and Virtue Trials

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$33.48M
Net Income
-$52.7M
Diluted EPS
-$1.11
Op. Cash Flow
-$48.96M
Free Cash Flow
-$49.45M
Gross Profit
$33.29M
Operating Income
-$51.81M
Cash & Equivalents
$34.69M
Debt / Equity
0.00×
Net Margin
-157.4%
Shares Outstanding
57.03M sh
Source: 10-K · filed 2026-03-12 · accession 0001104659-26-026754

Short Interest & Short Volume

6.99 days to cover

FINRA reported short interest of 2,732,484 shares in OBIO as of the October 30, 2026 settlement, a 7.0% increase from the prior period — about 7.0 days to cover at its recent average daily volume. On November 20, 2026, 34.0% of OBIO volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)2,732,484 shares as of October 30, 2026
Change vs prior period▲ 7.0%
Days to cover6.99 at avg daily volume of 390,641
Daily short volume (FINRA facilities)34.0% of 150,546 shares on November 20, 2026
5-day average short volume41.8%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for OBIO, detected from its recent SEC filings · based on capital-structure filings through 2026-11-06.

1 recent capital raise

15M Shares Priced at $5.00 · Net Proceeds About $70.0M

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with O →
$6.58
52-week range · as of 2026-11-12 $3.46 – $6.58
Market cap
$517.88M
Volume
554.4K (1.1× avg)
3-mo avg 523.4K
Live data · 2026-11-22 12:38 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed OBIO - Latest Insights

OBIO
Nov 12, 2026, 4:27 PM EST
Filing Type: 4
Importance Score:
7
Price at Filing: $6.23
Real-time Price: $6.58 info
Change: +$0.350 (+6%) info
Market Cap: $517.879M info
OBIO
Nov 10, 2026, 4:04 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $5.73
Real-time Price: $6.58 info
Change: +$0.850 (+15%) info
Market Cap: $517.879M info
OBIO
Nov 06, 2026, 5:11 PM EST
Filing Type: 424B5
Importance Score:
8
Updated Nov 9, 4:22 PM ET — Orchestra BioMed closed the offering on November 9, 2026, raising $86.3 million gross after underwriters fully exercised their 2,250,000-sh…
Price at Filing: $5.68
Real-time Price: $6.58 info
Change: +$0.900 (+16%) info
Market Cap: $517.879M info
OBIO
Nov 05, 2026, 10:43 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $5.00
Real-time Price: $6.58 info
Change: +$1.58 (+32%) info
Market Cap: $517.879M info
OBIO
Nov 05, 2026, 4:01 PM EST
Filing Type: 424B5
Importance Score:
7
Price at Filing: $5.56
Real-time Price: $6.58 info
Change: +$1.02 (+18%) info
Market Cap: $517.879M info
OBIO
Nov 05, 2026, 4:01 PM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $4.70
Real-time Price: $6.58 info
Change: +$1.88 (+40%) info
Market Cap: $517.879M info
OBIO
Oct 01, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $6.08
Real-time Price: $6.58 info
Change: +$0.500 (+8%) info
Market Cap: $517.879M info
OBIO
Aug 10, 2026, 4:20 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $4.46
Real-time Price: $6.58 info
Change: +$2.12 (+48%) info
Market Cap: $517.879M info
OBIO
Aug 10, 2026, 4:07 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $4.46
Real-time Price: $6.58 info
Change: +$2.12 (+48%) info
Market Cap: $517.879M info
OBIO
May 12, 2026, 4:11 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $4.06
Real-time Price: $6.58 info
Change: +$2.52 (+62%) info
Market Cap: $517.879M info
OBIO
May 12, 2026, 4:07 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $4.06
Real-time Price: $6.58 info
Change: +$2.52 (+62%) info
Market Cap: $517.879M info
OBIO
May 11, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $4.04
Real-time Price: $6.58 info
Change: +$2.54 (+63%) info
Market Cap: $517.879M info
OBIO
May 01, 2026, 4:16 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $3.97
Real-time Price: $6.58 info
Change: +$2.61 (+66%) info
Market Cap: $517.879M info
OBIO
Apr 30, 2026, 9:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.88
Real-time Price: $6.58 info
Change: +$2.70 (+70%) info
Market Cap: $517.879M info
OBIO
Apr 29, 2026, 5:37 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $3.80
Real-time Price: $6.58 info
Change: +$2.78 (+73%) info
Market Cap: $517.879M info
OBIO
Apr 29, 2026, 4:30 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $3.80
Real-time Price: $6.58 info
Change: +$2.78 (+73%) info
Market Cap: $517.879M info
OBIO
Mar 12, 2026, 8:03 AM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $4.55
Real-time Price: $6.58 info
Change: +$2.03 (+45%) info
Market Cap: $517.879M info
OBIO
Feb 25, 2026, 4:28 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $4.35
Real-time Price: $6.58 info
Change: +$2.23 (+51%) info
Market Cap: $517.879M info
OBIO
Jan 12, 2026, 9:12 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.98
Real-time Price: $6.58 info
Change: +$1.60 (+32%) info
Market Cap: $517.879M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets